Your browser doesn't support javascript.
loading
Combined treatment with inhibitors of ErbB Receptors and Hh signaling pathways is more effective than single treatment in reducing the growth of malignant mesothelioma both in vitro and in vivo.
Bei, Roberto; Benvenuto, Monica; Focaccetti, Chiara; Fazi, Sara; Moretti, Marta; Nardozi, Daniela; Angiolini, Valentina; Ciuffa, Sara; Cifaldi, Loredana; Carrano, Raffaele; Palumbo, Camilla; Miele, Martino Tony; Bei, Riccardo; Barillari, Giovanni; Manzari, Vittorio; De Smaele, Enrico; Modesti, Andrea; Masuelli, Laura.
Afiliación
  • Bei R; Department of Clinical Sciences and Translational Medicine, University of Rome "Tor Vergata", via Montpellier 1, 00133, Rome, Italy. bei@med.uniroma2.it.
  • Benvenuto M; Department of Clinical Sciences and Translational Medicine, University of Rome "Tor Vergata", via Montpellier 1, 00133, Rome, Italy.
  • Focaccetti C; Saint Camillus International University of Health and Medical Sciences, via di Sant'Alessandro 8, 00131, Rome, Italy.
  • Fazi S; Department of Clinical Sciences and Translational Medicine, University of Rome "Tor Vergata", via Montpellier 1, 00133, Rome, Italy.
  • Moretti M; Department of Experimental Medicine, University of Rome "Sapienza", viale Regina Elena 324, 00161, Rome, Italy.
  • Nardozi D; Department of Experimental Medicine, University of Rome "Sapienza", viale Regina Elena 324, 00161, Rome, Italy.
  • Angiolini V; Department of Experimental Medicine, University of Rome "Sapienza", viale Regina Elena 324, 00161, Rome, Italy.
  • Ciuffa S; Department of Experimental Medicine, University of Rome "Sapienza", viale Regina Elena 324, 00161, Rome, Italy.
  • Cifaldi L; Department of Clinical Sciences and Translational Medicine, University of Rome "Tor Vergata", via Montpellier 1, 00133, Rome, Italy.
  • Carrano R; Department of Clinical Sciences and Translational Medicine, University of Rome "Tor Vergata", via Montpellier 1, 00133, Rome, Italy.
  • Palumbo C; Academic Department of Pediatrics (DPUO), Ospedale Pediatrico Bambino Gesù, IRCCS, 00165, Rome, Italy.
  • Miele MT; Department of Clinical Sciences and Translational Medicine, University of Rome "Tor Vergata", via Montpellier 1, 00133, Rome, Italy.
  • Bei R; Department of Clinical Sciences and Translational Medicine, University of Rome "Tor Vergata", via Montpellier 1, 00133, Rome, Italy.
  • Barillari G; Department of Experimental Medicine, University of Rome "Tor Vergata", Via Montpellier 1, 00133, Rome, Italy.
  • Manzari V; Medical School, University of Rome "Tor Vergata", 00133, Rome, Italy.
  • De Smaele E; Department of Clinical Sciences and Translational Medicine, University of Rome "Tor Vergata", via Montpellier 1, 00133, Rome, Italy.
  • Modesti A; Department of Clinical Sciences and Translational Medicine, University of Rome "Tor Vergata", via Montpellier 1, 00133, Rome, Italy.
  • Masuelli L; Department of Experimental Medicine, University of Rome "Sapienza", viale Regina Elena 324, 00161, Rome, Italy.
J Transl Med ; 20(1): 286, 2022 06 25.
Article en En | MEDLINE | ID: mdl-35752861
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Receptores ErbB / Mesotelioma Maligno Límite: Animals / Humans Idioma: En Revista: J Transl Med Año: 2022 Tipo del documento: Article País de afiliación: Italia
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Receptores ErbB / Mesotelioma Maligno Límite: Animals / Humans Idioma: En Revista: J Transl Med Año: 2022 Tipo del documento: Article País de afiliación: Italia